

FORM 13-501F1
CLASS 1 AND CLASS 3B REPORTING ISSUERS - PARTICIPATION FEE

MANAGEMENT CERTIFICATION

I, Bernard Lessard, an officer of the reporting issuer noted below have examined this Form 13-501F1 (the **Form**) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised reasonable diligence, the information provided in the Form is complete and accurate.

(s) Bernard Lessard
 Name: Bernard Lessard Date: March 11, 2019
 Title: Chief Financial Officer

Reporting Issuer Name: TetraBio-Pharma Inc.
 End date of previous financial year: November 30, 2018
 Type of Reporting Issuer: ☒ Class 1 Reporting Issuer ☐ Class 3B Reporting Issuer
 Highest Trading Marketplace: Canadian Securities Exchange

Market value of listed or quoted equity securities:

Equity Symbol	<u>TBP</u>		<u>01/12/2017</u> (DD/MM/YY)	to	<u>28/02/2018</u> (DD/MM/YY)
1st Specified Trading Period					
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace					\$ <u>0.88</u> (i)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period					<u>127,228,759</u> (ii)
Market value of class or series				(i) x (ii)	\$ <u>111,961,307.92</u> (A)
			<u>01/03/2018</u> (DD/MM/YY)	to	<u>31/05/2018</u> (DD/MM/YY)
2nd Specified Trading Period					
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace					\$ <u>0.68</u> (iii)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period					<u>152,961,631</u> (iv)
Market value of class or series				(iii) x (iv)	\$ <u>104,013,909.08</u> (B)
			<u>01/06/2018</u> (DD/MM/YY)	to	<u>31/08/2018</u> (DD/MM/YY)
3rd Specified Trading Period					
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace					\$ <u>1.10</u> (v)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period					<u>153,916,631</u> (vi)
Market value of class or series				(v) x (vi)	\$ <u>169,308,294.10</u> (C)

	01/09/2018 (DD/MM/YY)	to	30/11/2018 (DD/MM/YY)	
4th Specified Trading Period				
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace			1.04 \$ _____	(vii)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period			162,831,631 _____	(viii)
Market value of class or series		(vii) x (viii)	169,344,896.24 \$ _____	(D)
5th Specified Trading Period	N/A (DD/MM/YY)	to	N/A (DD/MM/YY)	
Closing price of the security in the class or series on the last trading day of the specified trading period in which such security was listed or quoted on the highest trading marketplace			N/A \$ _____	(ix)
Number of securities in the class or series of such security outstanding at the end of the last trading day of the specified trading period			N/A _____	(x)
Market value of class or series		(ix) x (x)	N/A \$ _____	(E)
Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))			138,657,101.84 \$ _____	(1)
----- (Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)				
Fair value of outstanding debt securities			N/A \$ _____	(2)
(Provide details of how value was determined)				
Capitalization for the previous financial year		(1) + (2)	138,657,101.84 \$ _____	
Participation Fee			6,500 \$ _____	
Late Fee, if applicable			N/A \$ _____	
Total Fee Payable (Participation Fee plus Late Fee)			6,500 \$ _____	

RULES AND POLICIES

APPENDIX A

to ASC Rule 13-501 Fees

Participation Fees for Class 1 Reporting Issuers or Class 2 Reporting Issuers
(Paragraph 15(1)(a))

Capitalization for the Previous Fiscal Year	Participation Fee (effective December 1, 2016)
under \$10 million	\$400
\$10 million to under \$25 million	\$500
\$25 million to under \$50 million	\$1,200
\$50 million to under \$100 million	\$3,000
\$100 million to under \$250 million	\$6,500
\$250 million to under \$500 million	\$14,000
\$500 million to under \$1 billion	\$19,000
\$1 billion to under \$5 billion	\$28,000
\$5 billion to under \$10 billion	\$36,500
\$10 billion to under \$25 billion	\$42,500
\$25 billion and over	\$48,000

APPENDIX B

to ASC Rule 13-501 Fees

Participation Fees for Class 3B Reporting Issuers
(Paragraph 15(1)(c))

Capitalization for the Previous Fiscal Year	Participation Fee (effective December 1, 2016)
under \$10 million	\$400
\$10 million to under \$25 million	\$500
\$25 million to under \$50 million	\$600
\$50 million to under \$100 million	\$1,000
\$100 million to under \$250 million	\$2,000
\$250 million to under \$500 million	\$4,500
\$500 million to under \$1 billion	\$6,000
\$1 billion to under \$5 billion	\$9,000
\$5 billion to under \$10 billion	\$11,500
\$10 billion to under \$25 billion	\$13,500
\$25 billion and over	\$15,500